Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.[1][2] As of May 2017[update], it is in Phase II clinical trials for the treatment of diabetic macular edema.[3][4]
This drug is being developed by Regeneron Pharmaceuticals.[citation needed]
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.
Lokasi Pengunjung: 3.14.128.223